ArticleCell communication and signaling : CCS2026
Cytoplasmic retention of IRF3 binding Vimentin competitively with ERK1/2 mitigates acute myeloid leukemia through TFEB nuclear translocation.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid blasts. In this study, we investigated the role of interferon regulatory factor 3 (IRF3), a key transcription factor of type I interferon, in AML differentiation. Bone marrow mononuclear cell samples from cytogenetically normal AML patients were analyzed, revealing significantly elevated IRF3 protein levels. Knocking down IRF3 in THP-1 cells promoted PMA-induced cell differentiation while inhibiting proliferation, and subcutaneous implantation of these IRF3-knockdown cells into nude mice resulted in a significant reduction in both tumor volume and weight. Non-canonically, the differentiation inducer PMA inhibited the phosphorylation and nuclear translocation of IRF3 in THP-1 cells, and deletion of the nuclear localization sequence (NLS) of IRF3 significantly promoted cell differentiation marker expression. Furthermore, IRF3S386A, the phosphorylation site mutation, promoted PMA-induced AML cell differentiation, and relieved the AML leukemia burden in a disseminated intravenous xenograft leukemia model. Mechanistically, upon PMA stimulation, IRF3 was retained in the cytoplasm, where it competitively bound to Vimentin. This binding disrupted the interaction of Vimentin with p-ERK, a kinase that could phosphorylate and inhibit transcription factor EB (TFEB). Consequently, TFEB, whose phosphorylation was reduced due to the disrupted p-ERK activity, translocated to the nucleus, where it promoted the differentiation of AML cells. Translationally, the TFEB activator TA1 and the ERK inhibitor PD98059 both promoted cell differentiation, and mitigated the AML burden induced by IRF3 upregulation. In summary, IRF3 is highly expressed in AML, and its non-transcriptional cytoplasmic function is essential for regulating AML cell differentiation. Mechanistically, IRF3 binds to Vimentin in cytoplasm, which disrupts the Vimentin-p-ERK signaling axis and consequently promotes the nuclear translocation of TFEB. Our findings provide a mechanistic framework for exploring differentiation strategies in non‑M3 AML, and highlight its potential translational value for future experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.